Royalty Pharma Plc Cl A (RPRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 09-2025 | 06-2025 | 03-2025 | 12-2024 | |
| Sales | 621,990 | 609,291 | 578,665 | 568,247 | 593,641 |
| Gross Profit | 621,990 | 609,291 | 578,665 | 568,247 | 593,641 |
| Operating Expenses | 233,609 | 182,135 | 368,866 | 34,065 | 232,127 |
| Operating Income | 388,381 | 427,156 | 209,799 | 534,182 | 361,514 |
| Interest Expense | 94,171 | 79,564 | 68,668 | 65,261 | 65,761 |
| Other Income | 61,703 | 96,619 | -50,496 | -35,488 | 38,598 |
| Pre-tax Income | 355,913 | 444,211 | 90,635 | 433,433 | 334,351 |
| Net Income Continuous | 355,913 | 444,211 | 90,635 | 433,433 | 334,351 |
| Minority Interests | 141,708 | 155,994 | 60,459 | 195,084 | 126,137 |
| Net Income | $214,205 | $288,217 | $30,176 | $238,349 | $208,214 |
| EPS Basic Total Ops | 0.50 | 0.67 | 0.07 | 0.55 | 0.46 |
| EPS Basic Continuous Ops | 0.84 | 1.03 | 0.21 | 1.00 | 0.75 |
| EPS Diluted Total Ops | 0.49 | 0.67 | 0.07 | 0.55 | 0.46 |
| EPS Diluted Continuous Ops | 0.64 | 0.79 | 0.16 | 0.75 | 0.56 |
| EPS Diluted Before Non-Recurring Items | N/A | 1.17 | 1.14 | 1.06 | 1.15 |
| EBITDA(a) | $397,119 | $436,277 | $219,148 | $539,463 | $366,820 |